Cargando…

Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission

Obesity is considered an independent risk factor for increased hospital length of stay and can be an obstacle to a safe discharge. Although typically prescribed in the outpatient setting, initiating glucagon-like peptide-one receptor agonists (GLP-1RAs) in the inpatient setting can be efficacious in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Figueredo, Yaiseli, Cottone, Claudia, Ferreira, Tanira, Gonzalez, Jesus, Iacobellis, Gianluca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Endocrinology/Diabetes/Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972903/ https://www.ncbi.nlm.nih.gov/pubmed/36865977 http://dx.doi.org/10.7759/cureus.34331

Ejemplares similares

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review
por: Irfan, Huma, et al.
Publicado: (2023)

What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue
por: Klair, Nimra, et al.
Publicado: (2023)

Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists
por: Ahmed, Sana, et al.
Publicado: (2023)

A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats
por: Zhang, Qian, et al.
Publicado: (2019)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study
por: Kubota, Mitsunobu, et al.
Publicado: (2023)

Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism
por: Zou, Sifan, et al.
Publicado: (2023)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
por: Parab, Panah, et al.
Publicado: (2023)

Extreme Weight Loss and Psychosis as Presenting Signs of Thyrotoxicosis
por: Le, Thu Nhi, et al.
Publicado: (2021)

Association of Weight Loss With Improved Sexual Function in Females
por: Syed, Asghar Hussain, et al.
Publicado: (2021)

Successful Resolution of Glucose Toxicity With the Use of Fixed-Ratio Combination Injection of Basal Insulin and Short-Acting Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
por: Miura, Hiroshi, et al.
Publicado: (2022)

FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade
por: Idrees, Zarwa, et al.
Publicado: (2022)

Impact of a Community-Based Weight Loss Program on Renal Function
por: Schwasinger-Schmidt, Tiffany E, et al.
Publicado: (2020)

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
por: Shami, Dalia, et al.
Publicado: (2023)

Improving Access to Child and Adolescent Weight Loss Surgery: A Review of Updated National and International Practice Guidelines
por: Elkhoury, David, et al.
Publicado: (2023)

The Impact of Abdominoplasty vs Non-abdominoplasty on Weight Loss in Bariatric and Non-bariatric Malaysian Patients: A Multicentre Retrospective Study
por: Wan Makhtar, Wan Ratmaazila, et al.
Publicado: (2022)

Fasting Glucagon Level in Type 2 Diabetes and Impaired Glucose Tolerance and Its Association With Diabetes-Associated Clinical Parameters: A Study From Karachi, Pakistan
por: Abbas, Eraj, et al.
Publicado: (2021)

Olanzapine-Induced Hyponatremia Presenting with Seizure Requiring Intensive Care Unit Admission
por: McNally, Michelle A, et al.
Publicado: (2020)

AZP-3404, a Peptide Analog of IGFBP-2, Induces Weight Loss and Improves Glucose Metabolism in Leptin-Resistant db/db Mice
por: Culler, Michael D, et al.
Publicado: (2021)

Predictors of Neonatal Intensive Care Unit Admission and Adverse Outcomes Related to Gestational Diabetes
por: Al-shahrani, Abdullah M
Publicado: (2023)

OR28-5 Bile Acid Sequestration Accelerates Glucagon Receptor-Mediated Body Weight Loss in Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2019)

Aversion to Hospital Admission Due to Fear of COVID Infection Leading to Fatality From Diabetic Ketoacidosis
por: Mohammad Ashraf, Hasina, et al.
Publicado: (2021)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
por: Zaffina, Isabella, et al.
Publicado: (2023)

SAT149 In Vitro Characterization Of A Novel Long-acting Glucagon Analog (HM15136) And Its Potential Effect In Animal Models Of Chronic Hypoglycemic Diseases
por: Kim, Jung Kuk, et al.
Publicado: (2023)

Diabetes Mellitus and Related Admission Factors Among Hospitalized Patients in King Abdul-Aziz University Hospital in Jeddah, Saudi Arabia
por: Shikdar, Yasamen A, et al.
Publicado: (2022)

Perception of Overall Health, Weight Status, and Gaining Weight in Relationship With Self-Reported BMI Among High School Students
por: Khanna, Deepesh, et al.
Publicado: (2021)

THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes
por: Reddy Ankireddypalli, Anvitha, et al.
Publicado: (2023)

Pituitary Apoplexy (PA): Delayed Diagnosis of a Rare Clinical Syndrome in a Patient With a Known Pituitary Adenoma
por: Mehkri, Yusuf, et al.
Publicado: (2022)

SAT-655 Bile Acid Sequestration Synergistically Accelerates Glucagon Receptor-Stimulated Body Weight Loss in Diet-Induced Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2020)

SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY
por: Tyler Broome, David
Publicado: (2023)

Weight and Body Mass Index for Predicting Thyroxine Dose in Primary Hypothyroidism
por: Raashid, Kashif, et al.
Publicado: (2021)

Hypercalcemia in a Patient Diagnosed with a Vasoactive Intestinal Peptide Tumor
por: Ataallah, Basma, et al.
Publicado: (2020)

C-Peptide-Positive, Autoantibody-Negative Type 1 Diabetes Mellitus
por: Fenner, Rachel M, et al.
Publicado: (2022)

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

Could Fahr’s Syndrome Have More Than One Simultaneous Etiology?
por: Palu, Gabriele, et al.
Publicado: (2021)

Vasoactive Intestinal Peptide Tumor as the Cause of Persistent Diarrhea: A Diagnostic Challenge
por: Lopes, Sara, et al.
Publicado: (2022)

Insulin-associated Weight Gain in Type 2 Diabetes and Its Relation with Caloric Intake
por: Naeem, Nadeem, et al.
Publicado: (2019)

A Narrative Review on Intermittent Fasting as an Approachable Measure for Weight Reduction and Obesity Management
por: Janaswamy, Raghav, et al.
Publicado: (2022)

The Influence of Lockdown Due to the COVID-19 Pandemic on Weight Management in Patients With Obesity in Portugal
por: Gomes, Dora, et al.
Publicado: (2023)

Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea–hypnoea index (AHI)
por: Sprung, Victoria S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vvlbvu2tstv8e413e29mtucl71